The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
Support for biologics manufacturability and Industry 4.0 initiatives
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Subscribe To Our Newsletter & Stay Updated
